Atrolactamide

Atrolactamide

SCHEMBL78236

CC(O)(C(N)=O)c1ccccc1

nearest known ligand 0.65

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.65
KMT2A Q03164 1/20 0.65
CYP1A2 P05177 2/20 0.48
CYP2D6 P10635 2/20 0.48
KCNN4 O15554 7/20 0.47
CYP2C19 P33261 2/20 0.47
HIF1A Q16665 1/20 0.47
HDAC3 O15379 1/20 0.45
HDAC4 P56524 1/20 0.45
HDAC1 Q13547 1/20 0.45
HDAC7 Q8WUI4 1/20 0.45
HDAC2 Q92769 1/20 0.45
HDAC10 Q969S8 1/20 0.45
HDAC11 Q96DB2 1/20 0.45
HDAC8 Q9BY41 1/20 0.45
HDAC6 Q9UBN7 1/20 0.45
HDAC9 Q9UKV0 1/20 0.45
HDAC5 Q9UQL6 1/20 0.45
HTT P42858 1/20 0.44
TAAR1 Q96RJ0 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Atrolactamide SCHEMBL28842804 0.92 MAPT (0.57) MAPTKMT2ACYP1A2CYP2D6KCNN4
Atrolactamide SCHEMBL28201551 0.90 MAPT (0.55) MAPTKMT2ACYP1A2CYP2D6KCNN4
Atrolactamide SCHEMBL28875745 0.86 CA2 (0.52) MAPTKMT2ACYP1A2CYP2D6KCNN4
Atrolactamide SCHEMBL28540119 0.84 MAPT (0.49) MAPTKMT2ACYP1A2CYP2D6ALDH1A1
Atrolactamide SCHEMBL31758013 0.84 LMNA (0.58) MAPTKMT2ACYP1A2CYP2D6LMNA
Atrolactamide SCHEMBL6903234 0.84 MAPT (0.49) MAPTKMT2ACYP1A2CYP2D6KCNN4
SCHEMBL197251 0.81 MAPT (0.52) MAPTKMT2ACYP1A2CYP2D6KCNN4
SCHEMBL21557850 0.81 MAPT (0.52) MAPTKMT2ACYP1A2CYP2D6KCNN4
SCHEMBL198241 0.81 MAPT (0.52) MAPTKMT2ACYP1A2CYP2D6KCNN4
SCHEMBL4326795 0.81 MAPT (0.52) MAPTKMT2ACYP1A2CYP2D6KCNN4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1457 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120154546-A Preparation method of osmotic absorption mask 臧伟仲 2025-06-17 CN claimed
CN-119744164-A Odor and colorant stable compositions 西姆莱斯股份公司 2025-04-01 CN claimed
CN-119700634-A Anti-aging composition containing sheep placenta extract, application thereof and cosmetics 广州美姿生物科技有限公司 2025-03-28 CN claimed
CN-119454557-A Repairing and soothing liposome composition and preparation method and application thereof 广东科盈科技有限公司 2025-02-18 CN claimed
CN-119390602-A Synthesis process of hydroxyphenyl propionamide benzoic acid 青岛三人行化学有限公司 2025-02-07 CN claimed
CN-119345057-A A polypeptide containing polydeoxyribonucleotide and its preparing process sodium hyaluronate composition and application thereof 恒昱生物制药(山东)有限公司 2025-01-24 CN claimed
CN-119326695-A Composition capable of relieving chronic itch of skin, preparation method and application 春羽生物科技(无锡)有限公司 2025-01-21 CN claimed
CN-119185104-A Soothing composition, application and cosmetic 广州思瑞生物科技有限公司 2024-12-27 CN claimed
CN-119157807-A Hair care composition and preparation method thereof 广州科玛生物科技股份有限公司 2024-12-20 CN claimed
CN-119112688-A Whitening and freckle-removing facial cream and preparation method thereof 广东格烯生物科技股份有限公司 2024-12-13 CN claimed
WO-2005108393-A1 PYRROLE OR IMIDAZOLE AMIDES FOR TREATING OBESITY F. HOFFMANN-LA ROCHE AG (CH) 2005-11-17 WO claimed
US-20050250769-A1 Heterocyclic cannabinoid receptor antagonists F. HOFFMANN-LA ROCHE AG (CH) 2005-11-10 US claimed
WO-2004089364-A1 AZABICYCLO DERIVATIVES AS MUSCARINIC RECEPTOR ANTAGONISTS RANBAXY LABORATORIES LIMITED (IN) 2004-10-21 WO claimed
EP-1363906-A2 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2003-11-26 EP claimed
WO-2002064586-A2 HETEROCYCLIC INHIBITORS OF ERK2 AND USES THEREOF VERTEX PHARMACEUTICALS INCORPORATED (US) 2002-08-22 WO claimed
CN-1294519-A Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient INPHARMA SA (CH) 2001-05-09 CN claimed
EP-1073470-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2001-02-07 EP claimed
WO-2000048636-A1 PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS INPHARMA S.A. (CH) 2000-08-24 WO claimed
EP-0537259-A1 PROCESS FOR PRODUCING ENANTIOMERS OF 2-ARYL-ALKANOIC ACIDS NOVO NORDISK A/S (DK) 1993-04-21 EP claimed
WO-1992001062-A1 PROCESS FOR PRODUCING ENANTIOMERS OF 2-ARYL-ALKANOIC ACIDS NOVO NORDISK A/S (DK) 1992-01-23 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050250769-A1 Heterocyclic cannabinoid receptor antagonists CNR1, CNR2, GPR18 MAPT 4118/4885KMT2A 3110/4885CYP1A2 430/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.